10-Q: Greenwich LifeSciences Q2 Loss Widens, Going Concern Warning

Greenwich LifeSciences reported a significantly wider net loss in Q2 2025, driven by increased R&D and administrative expenses, while also disclosing substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the six months ended June 30, 2025, widened to $7,283,640, up from $5,079,877 in the same period of 2024.
• Research and development expenses increased by 36% to $6,109,028 for the six months ended June 30, 2025, primarily due to stock option grants and clinical expenses.
• General and administrative expenses rose by 75% to $1,219,257 for the six months ended June 30, 2025, also largely due to stock option grants.
• Cash balance decreased to $3,125,101 as of June 30, 2025, from $4,091,990 at December 31, 2024.
• The company continues to operate on a going concern basis, dependent on securing additional capital to fund future operations.
• Raised $3,100,668 in net proceeds from At-The-Market (ATM) offerings between January 1 and June 30, 2025, by selling 320,210 shares at an average price of $9.95 per share.
• Subsequent to the quarter, an additional $1,601,059 in net proceeds was raised from ATM offerings between July 1 and July 28, 2025, by selling 157,318 shares at an average price of $10.49 per share.
• Identified material weaknesses in internal control over financial reporting due to inadequate segregation of duties and insufficient written policies.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including widening losses, a declining cash balance, and a 'going concern' warning. While clinical trial progress is noted, the heavy reliance on dilutive equity financing at lower prices and identified internal control weaknesses contribute to a negative financial outlook.

Positives

• Continued progress in the Phase III clinical trial (Flamingo-01) for GLSI-100, with plans to expand into Europe with up to 150 sites globally.
• Successfully raised capital through At-The-Market (ATM) offerings, securing $3,100,668 net proceeds in H1 2025 and an additional $1,601,059 net proceeds in July 2025.
• No material legal proceedings are currently pending or threatened against the company.

Negatives

• Net loss significantly widened to $7,283,640 for the six months ended June 30, 2025, compared to $5,079,877 for the same period in 2024.
• Cash balance declined to $3,125,101 as of June 30, 2025, from $4,091,990 at December 31, 2024, indicating a high cash burn rate.
• The company has incurred net losses since inception and has negative operating cash flows, raising substantial doubt about its ability to continue as a going concern.
• Increased operating expenses, with R&D up 36% and G&A up 75% for the six months ended June 30, 2025, primarily due to stock-based compensation and clinical expenses.
• Identified material weaknesses in disclosure controls and procedures and internal control over financial reporting.
• Average offering price for ATM sales in H1 2025 ($9.95/share) and July 2025 ($10.49/share) is lower than H1 2024 ($14.07/share), suggesting potential share price depreciation and increased dilution to raise capital.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to accumulated net losses and negative operating cash flows.
• Dependence on obtaining additional capital through equity and/or debt securities, with no assurance of success.
• Expectation of continued significant expenses and increased operating losses for the foreseeable future as the company develops its pipeline and conducts clinical trials.
• Material weaknesses in internal control over financial reporting, specifically inadequate segregation of duties and insufficient written policies, which could affect financial reporting reliability.
• Reliance on third-party contract manufacturers for all raw materials, active pharmaceutical ingredients, and finished product candidates for clinical trials.
• Potential for costly legal expenses and reputational damage from disputes, even if management believes insurance will be adequate.
• The lock-up agreement for directors, officers, and pre-IPO investors expires March 31, 2026, potentially leading to increased selling pressure thereafter.

Future Outlook

We expect to continue to incur significant expenses and corresponding increased operating losses for the foreseeable future as we continue to develop our pipeline. Our costs may further increase as we conduct clinical trials and seek regulatory approval for and prepare to commercialize our product candidate. We anticipate incurring significant expenses to build the necessary infrastructure for expanded operations, clinical trials, and commercialization, including manufacturing, marketing, sales, and distribution functions, along with increased costs associated with operating as a public company. Our ability to continue operations is dependent upon obtaining additional capital.

Management Comments

• We expect to continue to incur significant expenses and corresponding increased operating losses for the foreseeable future as we continue to develop our pipeline.
• Our costs may further increase as we conduct clinical trials and seek regulatory approval for and prepare to commercialize our product candidate.
• We expect to incur significant expenses to continue to build the infrastructure necessary to support our expanded operations, clinical trials, commercialization, including manufacturing, marketing, sales and distribution functions.
• We will also experience increased costs associated with operating as a public company.
• For the foreseeable future, the Company's ability to continue its operations is dependent upon its ability to obtain additional capital.

Industry Context

Greenwich LifeSciences operates in the highly capital-intensive and high-risk biopharmaceutical industry, specifically in oncology. As a clinical-stage company with no revenue, its financial performance is typical for its development phase, characterized by significant R&D expenditures and net losses. The expansion of its Phase III clinical trial (Flamingo-01) into Europe is a standard progression for drug development, aiming to broaden patient recruitment and accelerate trial completion. The reliance on equity financing, such as ATM offerings, is common for pre-revenue biotech firms to fund ongoing research and clinical development, though it leads to shareholder dilution. The 'going concern' warning is a critical disclosure for companies at this stage, highlighting the inherent financial challenges and dependence on future funding.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• Unreimbursed expenses accrued by management totaled $82,852 as of June 30, 2025.
• Deferred bonus compensation of $306,281 for senior management for services provided in 2024.
• The company's month-to-month sub-lease for approximately $2,819 per month is from a related party.
• Accrued interest owed to The Henry M. Jackson Foundation (HJF) totals $220,845 as of June 30, 2025, related to the exclusive license agreement for GP2.

Stakeholder Impact

• Shareholders face significant dilution from ongoing At-The-Market (ATM) offerings, which are occurring at lower average prices than in the prior year. There is potential for further dilution due to the company's dependence on future capital raises, and a risk of substantial loss of investment due to the 'going concern' warning.
• Employees/Management receive significant stock-based compensation, but deferred bonus compensation for senior management indicates cash flow constraints.
• Creditors may have concerns about the company's ability to meet its financial obligations in the long term due to the 'going concern' warning.
• Patients and the medical community could see potential for a new breast cancer immunotherapy from the continued progress in the Phase III clinical trial for GLSI-100, but the financial instability could impact trial completion or future commercialization.

Next Steps

• Continue development of the breast cancer immunotherapy GLSI-100.
• Expand the Phase III clinical trial, Flamingo-01, into Europe with plans to open up to 150 sites globally.
• Remediate identified material weaknesses in internal control over financial reporting.
• Seek additional capital through equity and/or debt securities to meet long-term operating requirements.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by widening net losses, a rapidly declining cash balance, and an explicit 'going concern' warning. Its operations are entirely dependent on continuous, dilutive equity raises, which are occurring at decreasing average prices, indicating a deteriorating market perception and increasing shareholder dilution. The identified material weaknesses in internal controls further compound the risk. Without a clear path to profitability or substantial non-dilutive funding, the investment carries extreme risk, making a 'strong sell' recommendation appropriate for seasoned investors.

Keywords

Breast Cancer Immunotherapy, GLSI-100, GP2, Phase III Clinical Trial, Flamingo-01, Biopharmaceutical, Oncology, SEC 10-Q, Going Concern, ATM Offering, Clinical Stage